BioLineRx (BLRX) Competitors $2.94 -0.16 (-5.16%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$2.82 -0.13 (-4.25%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. NBRV, KZR, SPRO, CELU, CNTB, DTIL, ICCC, LTRN, RNTX, and KALAShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), Spero Therapeutics (SPRO), Celularity (CELU), Connect Biopharma (CNTB), Precision BioSciences (DTIL), ImmuCell (ICCC), Lantern Pharma (LTRN), Rein Therapeutics (RNTX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Nabriva Therapeutics Kezar Life Sciences Spero Therapeutics Celularity Connect Biopharma Precision BioSciences ImmuCell Lantern Pharma Rein Therapeutics KALA BIO Nabriva Therapeutics (NASDAQ:NBRV) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Do insiders and institutionals believe in NBRV or BLRX? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in NBRV or BLRX? BioLineRx received 114 more outperform votes than Nabriva Therapeutics when rated by MarketBeat users. Likewise, 71.61% of users gave BioLineRx an outperform vote while only 54.81% of users gave Nabriva Therapeutics an outperform vote. CompanyUnderperformOutperformNabriva TherapeuticsOutperform Votes39354.81% Underperform Votes32445.19% BioLineRxOutperform Votes50771.61% Underperform Votes20128.39% Do analysts rate NBRV or BLRX? BioLineRx has a consensus target price of $26.00, indicating a potential upside of 784.35%. Given BioLineRx's stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioLineRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, NBRV or BLRX? Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Which has higher valuation & earnings, NBRV or BLRX? Nabriva Therapeutics has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ABioLineRx$21.99M0.45-$60.61M-$8.80-0.33 Is NBRV or BLRX more profitable? BioLineRx has a net margin of -90.57% compared to Nabriva Therapeutics' net margin of -148.11%. BioLineRx's return on equity of -163.37% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% BioLineRx -90.57%-163.37%-34.21% Does the media favor NBRV or BLRX? In the previous week, BioLineRx had 17 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 17 mentions for BioLineRx and 0 mentions for Nabriva Therapeutics. BioLineRx's average media sentiment score of 0.53 beat Nabriva Therapeutics' score of 0.00 indicating that BioLineRx is being referred to more favorably in the news media. Company Overall Sentiment Nabriva Therapeutics Neutral BioLineRx Positive SummaryBioLineRx beats Nabriva Therapeutics on 12 of the 17 factors compared between the two stocks. Remove Ads Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.79M$6.72B$5.53B$7.50BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-0.336.9923.1218.08Price / Sales0.45198.60360.0289.38Price / CashN/A65.6738.1634.64Price / Book0.405.926.473.99Net Income-$60.61M$142.37M$3.21B$247.18M7 Day Performance-3.61%-7.24%-4.97%-4.25%1 Month Performance-4.23%-10.45%-0.14%-6.87%1 Year Performance-91.07%-14.58%6.19%-3.73% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx2.3175 of 5 stars$2.94-5.2%$26.00+784.4%-91.1%$9.79M$21.99M-0.3340Analyst ForecastAnalyst RevisionNews CoverageGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastKZRKezar Life Sciences4.05 of 5 stars$6.16+4.6%$39.50+541.2%-47.5%$44.94M$7M-0.4760Gap DownSPROSpero Therapeutics4.1518 of 5 stars$0.82-0.6%$5.00+511.6%-65.1%$44.57M$89.87M11.68150High Trading VolumeCELUCelularityN/A$1.87+2.7%N/A-71.1%$44.52M$48.20M0.00220Gap DownCNTBConnect Biopharma3.1825 of 5 stars$0.80-1.8%$8.00+900.0%-72.3%$44.20M$24.12M0.00110Analyst RevisionDTILPrecision BioSciences4.3571 of 5 stars$5.64+3.5%$37.67+567.8%-69.5%$43.26M$75.10M94.02200Short Interest ↓Gap DownICCCImmuCell0.2328 of 5 stars$4.78-2.6%N/A+2.9%$42.61M$26.49M-9.5670Positive NewsGap UpLTRNLantern Pharma1.9355 of 5 stars$3.90+2.1%N/A-62.4%$42.06MN/A-2.1920Analyst ForecastNews CoverageRNTXRein TherapeuticsN/A$1.93+1.0%N/AN/A$41.82MN/A-0.629Gap UpKALAKALA BIO3.7969 of 5 stars$6.86-0.9%$15.00+118.7%-40.9%$41.78M$3.89M-0.5530Earnings ReportAnalyst Forecast Remove Ads Related Companies and Tools Related Companies NBRV Competitors KZR Competitors SPRO Competitors CELU Competitors CNTB Competitors DTIL Competitors ICCC Competitors LTRN Competitors RNTX Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLRX Stock Free BLRX Stock Alerts